
Bioretec Q3'25: Necessary revisions ahead
In connection with its Q3 business review, Bioretec shed light on its situation and the commercial challenges of the RemeOs product family. The company is seeking new commercial momentum through recruitment and revisions to its distribution model. Further, the company is preparing a strategy update, which is to be launched by the end of the year. Bioretec's CEO Sarah Hubar-Fisher in an interview with analyst Antti Siltanen.
Topics:
00:00 Introduction
00:12 H1 figures revisions
01:20 Summary of the third quarter
02:34 Gross profit
03:51 Status of the RemeOs launch in Europe
04:48 Reasons for…
The skinny
The skinny isn't ready yet — notes appear once the transcript is processed.